Share
A popular class of diabetes medications called GLP-1R agonists (Trulicity and Rybelsus) may also protect against glaucoma in diabetic patients, according to a new study led by researchers in the Scheie Eye Institute at the University of Pennsylvania’s Perelman School of Medicine. The findings were published in the British Journal of Ophthalmology.
The researchers looked at retrospective data of 1,961 diabetic patients who were new users of this class of drugs and matched them to 4,371 unexposed control subjects. After 150 days on average, 10 patients in the medicated group were newly diagnosed with glaucoma (0.5 percent) compared to 58 patients (1.3 percent) in the control group. The findings suggest that GLP-1 receptor agonists may decrease a diabetic patient’s risk of developing glaucoma by half.
The findings are supported by a Penn Medicine study from 2020, which found that GLP-1R agonists reduced neuroinflammation and prevented retinal ganglion cell death in mice. This class of drugs has also shown similarly protective effects against Alzheimer’s and Parkinson’s diseases in animal models, and clinical trials are underway to test the medications against neurodegenerative diseases in humans.
It is estimated that over 300,000 Australians have glaucoma, with 50% being unaware they have it and is also the second leading cause of blindness worldwide. People with diabetes are twice as likely to develop the eye condition.
“It was very encouraging to see that a popular diabetes medication could significantly reduce the risk of developing glaucoma, and our study suggests that these medications warrant further study in this patient population,” says Qi N. Cui, MD, PhD, with Brian VanderBeek, MD, MPH, both assistant professors of Ophthalmology at Penn.
Original media release can be found here.
Researchers from the Indiana University School of Medicine hope to develop new glaucoma therapies by testing human neurons and a regenerative therapy to rescue dying visual neurons. They’ve received a new five year, US$2 million grant from the National Eye Institute for the project.
People of African ancestry are five times as likely as others to develop glaucoma and up to 15 times as likely to be blinded by the condition, but most research has used data from people of European ancestry.
We are inviting individuals who have accessed eyecare services previously to participate in a focus group discussion so that we can better understand what good eye care means to the patient.